By the time you reach your mid-forties, the concentration of NAD+ in your tissues may have fallen by as much as half compared to your thirties. And with it, a cascade of cellular maintenance systems begins to slow. This is not a theory about aging. It is a measurable biochemical reality, documented in peer-reviewed literature and increasingly central to how longevity medicine thinks about the biology of decline.
NAD+, or nicotinamide adenine dinucleotide, is not a vitamin, a supplement, or a wellness trend. It is a coenzyme. a molecular workhorse that sits at the center of some of the most fundamental processes in human biology. Understanding why it matters, why it falls, and what happens when it does is the first step toward any serious conversation about longevity medicine.
The Role of NAD+ in Human Biology
Nicotinamide adenine dinucleotide exists in every living cell. Its primary role is as an electron carrier in oxidative metabolism: it accepts electrons from nutrients and shuttles them into the mitochondrial electron transport chain, where they drive the production of adenosine triphosphate. ATP, the universal energy currency of the cell.
Without sufficient NAD+, mitochondria cannot efficiently complete oxidative phosphorylation. The result is a measurable reduction in cellular energy output. Not a dramatic collapse, but a slow, progressive diminishment that compounds over time across every organ system.
But ATP production is only half the story. NAD+ also functions as a required substrate. a raw material. For two enzyme families whose work is central to longevity biology:
Sirtuins (SIRT1–SIRT7) are a class of NAD+-dependent deacylase enzymes that regulate gene expression, mitochondrial biogenesis, circadian rhythm, and cellular stress response. Research published in PMC (NIH) describes sirtuins as key mediators of metabolic homeostasis, with SIRT1 in particular governing the interplay between NAD+ biosynthesis and circadian clock function. When NAD+ is insufficient, sirtuin activity falls. And with it, the downstream signaling that keeps cells functioning in an organized, well-regulated way.
PARP enzymes (poly-ADP ribose polymerases) are the primary responders to DNA strand breaks. When DNA is damaged. By oxidative stress, radiation, or normal replication errors. PARP enzymes consume NAD+ to initiate repair. The problem is that chronic low-grade DNA damage, which increases with age, keeps PARPs in a state of perpetual activation, steadily depleting the NAD+ pool. As research on NAD+ metabolism and aging in PMC documents, this PARP-driven consumption is one of the primary drivers of the age-associated NAD+ decline.
There is also CD38, a cell-surface enzyme whose expression increases with the chronic inflammation that characterizes aging. Sometimes called "inflammaging." CD38 degrades NAD+ as part of calcium signaling, and its rising activity with age contributes meaningfully to the depletion of the cellular NAD+ pool.
Why NAD+ Declines With Age
NAD+ levels are governed by a dynamic equilibrium between biosynthesis. The body's ability to make NAD+. And consumption, driven by the enzyme families above. Aging disrupts this balance on both sides.
On the production side, the efficiency of the NAD+ salvage pathway. The primary recycling mechanism, regulated by an enzyme called NAMPT (nicotinamide phosphoribosyltransferase). Diminishes with age. NAMPT activity, as documented in NIH research, is critical for the conversion of nicotinamide back to NAD+. As NAMPT function declines, the cell becomes less capable of regenerating the NAD+ it uses.
On the consumption side, the three drivers above. Sirtuin activity competing for substrate, PARP enzymes responding to increased DNA damage, and CD38 upregulation from chronic inflammation. All accelerate. The pool is being drained faster, and refilled more slowly.
The practical consequence: preclinical and clinical research on NAD+ precursors published in PubMed shows that NAD+ levels in human tissue decline by approximately 50% between the third and sixth decades of life. This decline has been documented in skeletal muscle, liver, brain tissue, and blood. It is not uniform across organ systems, but it is consistent and directional.
What Happens When NAD+ Falls?
The downstream effects of NAD+ depletion are not a single symptom but a pattern of interrelated cellular dysfunction. Clinically, the picture often looks like this:
- Reduced mitochondrial efficiency. Cells have less capacity to generate ATP, manifesting as fatigue, reduced exercise tolerance, and slower recovery from physical and cognitive demands.
- Impaired DNA repair. With less NAD+ available, PARP enzymes cannot complete DNA repair as effectively. Over time, unrepaired damage accumulates. Contributing to genomic instability, a hallmark of cellular aging.
- Blunted sirtuin signaling. SIRT1 and its family members regulate hundreds of gene targets involved in inflammation, metabolism, and stress resistance. Reduced sirtuin activity has been associated in preclinical models with accelerated features of aging at the tissue level, as reviewed in the NAD+ and sirtuins in aging literature.
- Disrupted circadian regulation. SIRT1 and NAMPT are deeply intertwined with circadian clock function. Declining NAD+ levels may contribute to the fragmented sleep architecture and circadian drift frequently observed in older adults.
- Increased oxidative burden. NAD+ participates in cellular redox balance. Its depletion shifts cells toward a more oxidized state, amplifying the oxidative stress that accelerates cellular senescence.
None of these processes operates in isolation. They form a mutually reinforcing cascade. Which is precisely why NAD+ decline is considered by many longevity researchers to be one of the more consequential biochemical changes associated with aging.
Approaches to Restoring NAD+ Levels
Restoring or sustaining NAD+ levels requires addressing the biosynthetic side of the equation. Several approaches have been studied clinically.
NAD+ precursors. Primarily nicotinamide mononucleotide (NMN) and nicotinamide riboside (NR). Are oral compounds that enter the NAD+ biosynthetic pathway upstream of the coenzyme itself. Both have been evaluated in human clinical trials. A review of preclinical and clinical evidence on NAD+ precursors found that precursor supplementation can raise measurable NAD+ levels in blood, with evidence of downstream effects on mitochondrial function and inflammatory markers in some study populations. The evidence base is still maturing, and results have been variable across populations and biomarker endpoints.
Direct NAD+ infusion represents a more direct approach. Rather than relying on the biosynthetic pathway. Which may itself be compromised in aging. Intravenous or subcutaneous administration delivers NAD+ directly into circulation, allowing for more predictable elevation of systemic levels. Clinician-supervised protocols using injectable NAD+ have been employed in clinical settings for metabolic support, cognitive function, and recovery applications. As NAD+ IV therapy clinical guidance notes, the injectable route bypasses the absorption variability and first-pass metabolism limitations of oral precursors.
It is worth noting that the research landscape for NAD+ restoration is active and evolving. No approach has been validated in large-scale randomized trials for longevity outcomes in healthy adults. What exists is a mechanistically coherent rationale supported by a growing body of preclinical data and early human studies. a foundation that warrants serious clinical attention, not breathless promises.
What to Expect From a Clinician-Supervised NAD+ Protocol
At AnthologyRX, NAD+ is not offered as a supplement or a wellness add-on. It is part of a structured, clinician-supervised approach to cellular optimization. One that begins with individual clinical evaluation and laboratory assessment before any protocol is initiated.
A clinician-supervised NAD+ protocol at AnthologyRX typically involves baseline laboratory evaluation. Including a basic metabolic panel, liver function tests, and a complete blood count. To establish the patient's current metabolic status and rule out contraindications. Protocol structure, dosing, and administration route are individualized to the patient's clinical picture.
What patients may reasonably expect: this is not an overnight transformation. NAD+ restoration is a substrate-level intervention. It creates conditions for cellular systems to work more effectively, not a pharmacological override. Patients who respond well often report improvements in energy consistency, mental clarity, and physical recovery over weeks to months. Individual responses vary, and clinicians will monitor and adjust protocols based on clinical feedback and follow-up labs.
NAD+ protocols at AnthologyRX are compounded by a licensed 503A pharmacy and prescribed by licensed clinicians following individual clinical evaluation. Not all patients qualify for NAD+ therapy. The goal is not to sell a protocol. It is to determine whether, for a given patient, restoring NAD+ levels is a clinically appropriate and well-founded intervention in their broader longevity strategy.
Longevity medicine does not deal in certainties. What it deals in is mechanisms. Understanding what is happening at the cellular level and intervening with precision where the evidence supports it. NAD+ decline is one of the best-characterized features of biological aging. Whether and how to address it is a clinical question best answered in partnership with a clinician who understands both the science and the individual.
If you are ready to explore what a clinician-supervised protocol might look like for you, start here.